Abstract
Introduction
During acute viral infections, both innate and adaptive immunity work together contribute to the clearance of the pathogens [1] . Many acute infections stimulate massive CD8 + cytotoxic T lymphocyte (CTL) responses that play an important role in controlling invading viruses and these responses are divided into three phases: expansion, contraction and memory [1] . In the expansion phase, the infectious pathogen triggers proliferation of effector CTLs cytolytic to virus-infected cells. This is followed by the contraction phase, where 90% -95% of effector CTLs die of apoptosis induced by cytolytic granzyme-B (GB)-mediated lethal hit, which is produced by regulatory T (Treg) cells [2] . Typically, only 5% -10% of the expanded ensemble of CTLs survive and proceed in the final stage to constitute the long-term memory CTLs capable of turning on rapid responses, when re-encounting the same pathogen [1] .
Although CTLs are effective in controlling acute viral infections, they often become functionally deficient or exhausted in chronic infections due to persistent pathogen presence [3] . The common characteristic of chronic infections, such as human immunodeficiency virus [4] , hepatitis C virus (HCV) or hepatitis B virus (HBV) is that anti-virus CTLs are initially stimulated, but later become quantitatively and qualitatively defective leading to a stepwise progression of functional exhaustion and incapability of clearing pathogens [3] . Phenotypically, these exhausted CTLs express some immune inhibitory molecules, such as programmed death-1 (PD-1), T-cell Ig and mucin protein-3 (TIM-3), and lymphocyte-activation gene 3 (LAG-3) [3] [5] [6] . This makes CTLs ineffective in the stimulation-induced i) production of cytokines, including IL-2 and IFN-γ [7] , ii) cell proliferation, and iii) cytolytic effect on virus-infected cells [8] [9] [10] [11] .
Severe CTL exhaustion often strongly correlates with high viral loads [12] . It has been found that longer duration of the chronic infection or severe loss of CD4 + T cell help often leads to more serious CTL exhaustion [1] [13] , and the final stage of CTL exhaustion often results in depletion of virus-specific CTLs [8] [10] . Armstrong strain induces an acute viral infection, whereas LCMV clone 13 infection results in viremia that can last up to 3 months with virus persisting in the brain and kidneys [10] , leading to a chronic viral infection [14] . [18] . We also found that the PD-1 blockade efficiently converts CTL exhaustion in the OVA-specific chronic infection model [19] .
IL-21 cytokine was originally found to be produced by CD4 + T cells [20] and to serve as a "third" signal, functioning in concert with T cell receptor (TCR) activation and T cell co-stimulation to trigger CD8 + T cell responses [21] . Recently, it has been shown that IL-21 plays a significant role in controlling chronic LCMV We previously developed a novel ovalbumin (OVA)-specific exosome (EXO)-targeted T cell-based (OVA-T EXO ) vaccine by using non-specific polyclonal T cells with the uptake of OVA-specific dendritic cell (DC)-released EXO via the CD54/LFA-1 interaction [29] . We demonstrated that the OVA-Texo vaccine was able to directly stimulate potent OVA-specific CTL responses in the absence of CD4 + T cell help by counteracting CD4 + 25 + FoxP3 + regulatory T (Treg) cell suppression [29] [30]. We also developed an HIV-1 Gag-specific T cell-based vaccine, Gag-T EXO , by using non-specific polyclonal T cells with the uptake of Gag-specific DC-released EXO and demonstrated that the Gag-T EXO vaccine triggered potent Gag-specific immunity against Gag-expressing tumors in transgenic HLA-A2 mice [31] . To enhance its immunogenicity, we generated the former one triggered potent therapeutic immunity [32] . It also induced an efficient conversion of CTL exhaustion via its CD40L-dependent signaling activation of the mTORC1 pathway in chronic infection models [18] .
In this study, we constructed a recombinant adenovirus (AdV IL-21 ) expressing   mouse IL-21 and generated new OVA-T EXO/IL-21 and Gag-T EXO/IL-21 vaccines engineered to express IL-21 by infection of the above OVA-T EXO and Gag-T EXO cells with AdV IL-21 as previously described [32] . We assessed the effectiveness of the 
Preparation of Dendritic Cells and Dendritic Cell-Released Exosomes
Bone marrow-derived dendritic cells (DCs) were obtained by culturing bone marrow cells of wild-type (WT) B6 mice in culture medium containing granulocyte monocyte colony-stimulating factor (GM-CSF) (20 ng/ml) and IL-4 (20 ng/ml) for six days, as previously described [29] . DCs were pulsed with OVA (0.5 mg/ml) for overnight and termed DC OVA . DC OVA stained with various Abs were analysed by flow cytometry. DC OVA -released exosomes (EXO OVA ) were then purified from DC OVA culture supernatants by differential ultracentrifugation [29] .
In addition, DCs were also infected with AdV Gag (100 pfu/cell) for overnight in a humidified 37˚C, 5% CO 2 incubator, and termed DC Gag . DC Gag -released EXOs were purified from DC Gag culture supernatants by ultracentrifugation and termed EXO Gag .
Preparation of ConA-Stimulated Polyclonal T Cells
Polyclonal naïve CD8 + T cells were isolated from WT B6 mouse spleens, enriched by passage through nylon wool columns, and then purified by negative selection using anti-mouse CD4 paramagnetic beads (Life Technologies, Waltham, MA), as previously described [34] [35] . Purified polyclonal CD8 + T cells were cultured for 3 days in RPMI 1640 medium, containing IL-2 (20 U/ml) and ConA (1 μg/ml). CD8 + T cells were then purified from ConA-activated T cells using MACS anti-CD8 microbeads (Miltenyi Biotech, Auburn, CA) to yield CD8 + T cell populations with >95% purity [29] , and termed ConA-T cells.
Preparation of the OVA-TEXO/IL-21 and Gag-TEXO/IL-21 Vaccines and the Control OVA-TEXO/Null and Gag-TEXO/Null Vaccines
The OVA-T EXO and Gag-T EXO vaccines were generated by the incubation of CD8 + ConA-T cells with EXO OVA or EXO Gag at 3 × 10 6 cells/10 µg for 1 hour at 37˚C, followed by the transfection of T cells with the uptake of EXO OVA or EX-O Gag with AdV 41BBL at 100 pfu/cell for another 2 hours to form the vaccines, as previously described [32] . 
Flow Cytometric Analysis
Peripheral blood samples derived from AdV OVA -B6 and rLmOVA-B6 mice were 
Western Blot Analysis
EXO ( 
Electron Microscopy
EXO were fixed in 4% paraformaldehyde. The pellets were loaded onto carbon-coated formvar grids. The exosome sample-loaded grids were stained with saturated aqueous uranyl and then, examined with a JEOL 1200EX electron microscope at 60 kV.
Animal Studies
To cells/mouse). The mice were sacrificed 3 weeks after tumor cell injection, and the lung metastatic B16 melanoma colonies were counted in a blind fashion. Metastatic B16 melanoma colonies on freshly isolated lungs appeared as black color foci that were easily distinguishable from normal lung tissues. Metastasis was also confirmed by histological examination.
Statistical Analyses
Statistical analyses were performed with the Mann-Whitney U test using Prism 
Results

Preparation of the Transgene IL-21-Engineered T Cell-Based OVA-TEXO/IL-21 Vaccine
We constructed a replication-deficient transgene IL-21-expressing recombinant adenovirus AdV IL-21 by recombinant DNA technology as we described in MATERIALS & METHODS (Figure 1(a) ) [18] [32]. B6 mouse dendritic cells were generated by culturing B6 mouse bone marrow cells in the culture medium containing GM-CSF and IL-4 for six days, pulsed with OVA for overnight and termed DC OVA [18] [32]. OVA-specific exosomes (EXO OVA ) were purified from DC OVA culture supernatants by ultracentrifugation, and analyzed by electron microscopy and Western blotting analyses, respectively. We demonstrated that EXO OVA had exosomal "saucer" or round shape with 50 -90 nm in diameter (Figure 1(b) ) and contained EXO-associated proteins such as CD9 and LAMP-1 (Figure 1(c) ) [37] . We infected the OVA-T EXO cells [32] with AdV IL-21 to generate a transgene IL-21-engineered T cell-based vaccine, OVA-T EXO/IL-21 . IL-21 secretion in OVA-T EXO/IL-21 culture supernatants was estimated to be ~200 pg/ml using IL-21 ELISA kit. In contrast, there was no IL-21 detected in OVA-T EXO culture supernatants. 
OVA-TEXO/IL-21 Vaccine
OVA-Expressing Adenovirus Induces an OVA-Specific Chronic Infection in Mice with CTL Exhaustion
We previously found that infection of B6 mice with AdV OVA, led to establishment of an OVA-specific chronic infection mouse model with OVA-specific CTL inflation and exhaustion [18] . To develop acute and chronic infection models, B6 mice were i.v. infected with OVA-expressing recombinant rLmOVA bacteria and AdV OVA , respectively, followed by the kinetic analysis of OVA-specific CTL responses [18] . We demonstrated that AdV OVA infection resulted in OVA-specific memory CD8 + T cell inflation, when compared to CTLs developed in rLmO-VA-immunized mice (Figure 3(a) indicating that these CTLs may be exhausted. To further confirm it, we assessed the functional effect (expression of the effector cytokine IFN-γ) of these CTLs by flow cytometry. We showed that ~72% OVA-specific CTLs were IFN-γ positive in rLmOVA-B6 mice, compared to only ~10% OVA-specific CTLs were IFN-γ positive in rLmOVA-B6 mice (Figure 3(c) 
The OVA-TEXO/IL-21 Vaccine Converts CTL Exhaustion in Chronic Infection
We examined in our next set of experiments, whether the OVA-T EXO/IL-21 vaccine converts CTL exhaustion in chronic infection. The AdV OVA -B6 mice were boosted with OVA-T EXO/IL-21 and the control OVA-T EXO/Null vaccine. Four days after the boost, cell proliferation and intracellular IFN-γ expression of OVA-specific CTLs were assessed by flow cytometry. We demonstrated that there were ~6-fold (5.20% vs 0.81%) of CTL increase in OVA-T EXO/IL-21 -boosted mouse peripheral blood, which is more than ~3-fold of CTL increase in the control OVA-T EXO/Null -boosted mouse peripheral blood at day 4 after the boost (Figure 4(a) ), indicating that OVA-T EXO/IL-21 vaccine can more potently convert CTL exhaustion by significantly stimulating the proliferation of previously exhausted CTLs. We next assessed expression of an effector T cell cytokine, IFN-γ, in exhausted CTLs on a "per-cell" basis by intracellular staining of T cell IFN-γ. We demonstrated that only ~20% of OVA-specific CTLs were IFN-γ positive in AdV OVA -B6 mice (Figure 4(b) ). In OVA-T EXO/Null -and OVA-T EXO/IL-21 -boosted AdV OVA -B6 mice, however, we found ~60% and ~75% of IFN-γ-producing CTLs in the total OVA-specific CTLs, respectively (Figure 4(b) ), confirming that OVA-T EXO/IL-21 vaccine more potently converts CTL exhaustion in chronic infection by not only increasing the number of CTLs, but also restoring CTL functional effect.
OVA-Texo Converts CTL Exhaustion through the Activation of the mTORC1 Pathway
We previously showed that the OVA-T EXO vaccine rescued exhausted CTLs in chronic infection via its CD40L signaling, inducing the activation of the mTORC1 pathway [18] . Four days after the boost, cell phenotypes of the OVA-specific CTLs were assessed by flow cytometry to examine, whether the OVA-T EXO/IL-21 vaccine activates the mTORC1 pathway. We analyzed CTLs for the phosphorylation status of mTORC1-regulated EIF4E (pEIF4E) and for the intracellular expression of the transcription factor T-bet by flow cytometry. We determined that OVA-specific CTLs up-regulated levels of phospho-EIF4E and T-bet in OVA-T EXO/Null -boosted AdV OVA -B6 mice (Figure 4(a) ), which was consistent with our previous report [18] . Interestingly, the intracellular expression of pEIF4E and T-bet in OVA-specific CTLs was significantly higher in the OVA-T EXO/IL-21 -boosted AdV OVA -B6 mice than that in the OVA-T EXO/Null -boosted AdV OVA -B6 mice (pEIF4E, p = 0.02; T-bet, p = 0.001) (Figure 4 
Discussion
The inhibitory PD-1 molecule was originally found on active T cells following We previously developed a novel OVA-specific EXO-targeted T cell-based OVA-T EXO vaccine by using non-specific polyclonal T cells with the uptake of OVA-specific DC-released EXO [29] . We found that the OVA-Texo vaccine was able to directly stimulate potent OVA-specific CTL responses by counteracting CD4 + 25 + FoxP3 + Treg-induced CTL suppression [29] [30] . We also demonstrated that the 4-1BBL-expressing OVA-T EXO vaccine triggered an enhanced therapeutic immunity in WT B6 mice [32] and induced an efficient conversion of CTL exhaustion in chronic infection model via the CD40L-initiated signaling through the mTORC1 pathway [18] . In this study, we generated new OVA-T EXO/IL-21 and . We originally generated HIV-1 Gag-specific Gag-T EXO vaccine by using polyclonal
ConA-T cells with the uptake of Gag-specific DC-released EXO, and demonstrated that Gag-T EXO stimulated Gag-specific CTL responses in transgenic HLA-A2 mice [31] . We also generated a 4-1BBL-expressing Gag-T EXO vaccine capable of triggering more efficient CTL responses and therapeutic immunity against Gag-expressing tumor challenges than the original Gag-T EXO vaccine [32] . In this study, we have generated a new Gag-T EXO/IL-21 vaccine engineered to signals. Therefore, this study is likely to have a strong impact on developing new therapeutic vaccines that might be used as monotherapies or in combination with other HIV-1 blockades for treating immune deficiency syndrome patients.
